BLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
XIAFLEX (collagenase clostridium histolyticum) by Auxilius Pharma is conditions, resulting in lysis of collagen deposits. First approved in 2010.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIAFLEX is a biologic injectable containing collagenase clostridium histolyticum that enzymatically disrupts collagen deposits. It is approved for Dupuytren's contracture and Peyronie's disease, two conditions characterized by abnormal collagen accumulation. The drug works by lysing Type I and III collagen in plaques and cords, reducing deformity and patient symptoms.
$0.066BPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D penetration (~6,200 annual claims), signaling a niche market with likely lean team structure.
Mechanism of Action
conditions, resulting in lysis of collagen deposits. Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord. The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XIAFLEX at Auxilius Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.